JAX Recieves $28.3M of NIH Funding for Knockout Mouse Project
News Aug 05, 2016
JAX Professor and Janeway Distinguished Chair Robert Braun, Ph.D., is the principal investigator of the grant, with co-investigators Stephen Murray, Ph.D., and Karen Svenson, Ph.D.
“Mice and humans share approximately 20,000 genes,” Braun says, “but scientists have little or no data for more than half of these genes.” He says that scientists around the world have been working together since 2006 to generate a targeted knockout mutation for every gene in the mouse genome. “Deleting individual genes in this way provides valuable clues to the genes’ function.”
JAX and two other NIH funded centers are part of a worldwide effort, the International Mouse Phenotyping Consortium (IMPC), to genetically and systematically determine the function of every mammalian gene, one gene at a time. The consortium is engaged in the immense task of producing and phenotyping (collecting physiological data from) these mice. Mouse models of genes with common functionality between mice and humans can lead to new models of human disease, which are useful for drug screening, preclinical studies and deeper understanding of biological and disease mechanisms.
Under the new grant, Braun says, JAX will take advantage of powerful new gene editing technology, known as CRISPR/Cas9, to generate, breed, cryopreserve and clinically assess the health and well-being of 1,000 lines of mice. The research team will work with the scientific community to select genes of exceptional interest, genes for which little is presently known, and genes predicted to function in select pathways.
For each of the new mouse lines, JAX will assess body weight and composition, metabolic and physiological parameters, and behavioral and cognitive function at several age points, and make both the mice and the resulting data available to the worldwide scientific community prior to publication.
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE